PURPOSE: Childhood cancer survivors (CCSs) are at risk for physical disability. The aim of this investigation was to characterize and compare physical performance among CCSs and a group of siblings age < 18 years and determine if diagnosis, treatment, and physical activity levels were associated with lower performance scores. METHODS: CCSs ≥ 5 years from diagnosis and a sibling comparison group were recruited and evaluated for strength, mobility, and fitness. Physical performance measures were compared in regression models between survivors and siblings by diagnosis and among survivors by treatment exposures and physical activity levels. RESULTS: CCSs (n = 183; mean age ± standard deviation [SD], 13.5 ± 2.5 years; 53% male) scored lower than siblings (n = 147; mean age ± SD, 13.4 ± 2.4 years; 50% male) on lower-extremity strength testing, the timed up-and-go (TUG) test, and the 6-minute walk (6MW) test, despite reporting similar levels and types of habitual physical activity. The lowest scores were prevalent among survivors of CNS tumors and bone and soft tissue sarcomas on strength testing (score ± SD: CNS tumors, 76.5 ± 4.7; sarcoma 67.1 ± 7.2 v siblings, 87.3 ± 2.4 Newton-meters quadricep strength at 90° per second; P = .04 and .01, respectively) and among CNS tumor survivors on the TUG (score ± SD: 5.1 ± 0.1 v siblings, 4.4 ± 0.1 seconds; P < .001) and 6MW tests (score ± SD: 533.3 ± 15.6 v siblings, 594.1 ± 8.3 m; P < .001). CONCLUSION: CCSs may have underlying physiologic deficits that interfere with function that cannot be completely overcome by participation in regular physical activity. These survivors may need referral for specialized exercise interventions in addition to usual counseling to remain physically active.
PURPOSE: Childhood cancer survivors (CCSs) are at risk for physical disability. The aim of this investigation was to characterize and compare physical performance among CCSs and a group of siblings age < 18 years and determine if diagnosis, treatment, and physical activity levels were associated with lower performance scores. METHODS: CCSs ≥ 5 years from diagnosis and a sibling comparison group were recruited and evaluated for strength, mobility, and fitness. Physical performance measures were compared in regression models between survivors and siblings by diagnosis and among survivors by treatment exposures and physical activity levels. RESULTS: CCSs (n = 183; mean age ± standard deviation [SD], 13.5 ± 2.5 years; 53% male) scored lower than siblings (n = 147; mean age ± SD, 13.4 ± 2.4 years; 50% male) on lower-extremity strength testing, the timed up-and-go (TUG) test, and the 6-minute walk (6MW) test, despite reporting similar levels and types of habitual physical activity. The lowest scores were prevalent among survivors of CNS tumors and bone and soft tissue sarcomas on strength testing (score ± SD: CNS tumors, 76.5 ± 4.7; sarcoma 67.1 ± 7.2 v siblings, 87.3 ± 2.4 Newton-meters quadricep strength at 90° per second; P = .04 and .01, respectively) and among CNS tumor survivors on the TUG (score ± SD: 5.1 ± 0.1 v siblings, 4.4 ± 0.1 seconds; P < .001) and 6MW tests (score ± SD: 533.3 ± 15.6 v siblings, 594.1 ± 8.3 m; P < .001). CONCLUSION: CCSs may have underlying physiologic deficits that interfere with function that cannot be completely overcome by participation in regular physical activity. These survivors may need referral for specialized exercise interventions in addition to usual counseling to remain physically active.
Authors: Margaux B Gilliam; Avi Madan-Swain; Kimberly Whelan; Diane C Tucker; Wendy Demark-Wahnefried; David C Schwebel Journal: J Pediatr Psychol Date: 2011-10-17
Authors: Meredith A Wampler; Mary Lou Galantino; Sujuan Huang; Laura S Gilchrist; Victoria G Marchese; G Stephen Morris; David A Scalzitti; Melissa M Hudson; Kevin C Oeffinger; Marilyn Stovall; Wendy M Leisenring; Gregory T Armstrong; Leslie L Robison; Kirsten K Ness Journal: J Cancer Surviv Date: 2011-06-18 Impact factor: 4.442
Authors: Matthew C Hocking; Lisa A Schwartz; Wendy L Hobbie; Branlyn Werba Derosa; Richard F Ittenbach; Jun J Mao; Jill P Ginsberg; Anne E Kazak Journal: Pediatr Blood Cancer Date: 2012-03-20 Impact factor: 3.167
Authors: Liisa S Järvelä; Harri Niinikoski; Päivi M Lähteenmäki; Olli J Heinonen; Jukka Kapanen; Mikko Arola; Jukka Kemppainen Journal: J Cancer Surviv Date: 2010-06-15 Impact factor: 4.442
Authors: Elizabeth N Williams; Sara G Carroll; Dinah S Reddihough; Bev A Phillips; Mary P Galea Journal: Dev Med Child Neurol Date: 2005-08 Impact factor: 5.449
Authors: Lillian R Meacham; James G Gurney; Ann C Mertens; Kirsten K Ness; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Date: 2005-04-15 Impact factor: 6.921
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Stanley H Hung; Anne Rankin; Naznin Virji-Babul; Sheila Pritchard; Christopher Fryer; Kristin L Campbell Journal: Physiother Can Date: 2017 Impact factor: 1.037
Authors: Tejaswi Kandula; Michelle Anne Farrar; Richard J Cohn; David Mizrahi; Kate Carey; Karen Johnston; Matthew C Kiernan; Arun V Krishnan; Susanna B Park Journal: JAMA Neurol Date: 2018-08-01 Impact factor: 18.302
Authors: Kirsten K Ness; Gregory T Armstrong; Mondira Kundu; Carmen L Wilson; Tamara Tchkonia; James L Kirkland Journal: Cancer Date: 2014-12-19 Impact factor: 6.860
Authors: Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer Journal: Lancet Oncol Date: 2015-03 Impact factor: 41.316
Authors: Anne Stone; Danielle Novetsky Friedman; Brian H Kushner; Suzanne Wolden; Shakeel Modak; Michael P LaQuaglia; Jessica Costello; Xian Wu; Nai-Kong Cheung; Charles A Sklar Journal: Pediatr Blood Cancer Date: 2019-08-12 Impact factor: 3.167
Authors: Vesile Yildiz Kabak; Patrick Calders; Tulin Duger; Jibril Mohammed; Eric van Breda Journal: Support Care Cancer Date: 2018-09-25 Impact factor: 3.603
Authors: Melinda R Stolley; Lisa K Sharp; Christy C Tangney; Linda A Schiffer; Claudia Arroyo; Yoonsang Kim; Richard T Campbell; Mary Lou Schmidt; Kathleen Breen; Karen E Kinahan; Kim J Dilley; Tara O Henderson; Allen D Korenblit; Katya Seligman Journal: Cancer Date: 2015-01-06 Impact factor: 6.860
Authors: Michael W Bishop; Kirsten K Ness; Chenghong Li; Wei Liu; Deo Kumar Srivastava; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Alberto S Pappo; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-04 Impact factor: 4.254
Authors: Ellen M Lavoie Smith; Lang Li; ChienWei Chiang; Karin Thomas; Raymond J Hutchinson; Elizabeth M Wells; Richard H Ho; Jodi Skiles; Arindom Chakraborty; Celia M Bridges; Jamie Renbarger Journal: J Peripher Nerv Syst Date: 2015-03 Impact factor: 3.494